Hemostasis, Thrombosis & Coagulation

40 entries, newest first.

• 0053 — What is the risk of intracranial hemorrhage (ICH) at birth in newborns with hemophilia?
• 0052 — Do plasma emicizumab levels correlate with risk of bleeding?
• 0051 — How do you prescribe and monitor antithrombin inhibitor therapy?
• 0050 — What is the rate of thrombosis in Glanzmann patients who are treated with rFVIIa?
• 0049 — What is Quebec platelet disorder? How do you make the diagnosis, and what is the management?
• 0048 — What is the estimated annualized bleeding rate (ABR) for patients with severe hemophilia A with on-demand therapy vs prophylaxis?
• 0045 — What is the mechanism of action of efgartigimod and response rates in ITP?
• 0044 — What is the role of genetic testing in the diagnosis of bleeding disorder of unknown cause (BDUC)?
• 0043 — What treatment options are available to manage heavy menstrual bleeding in women receiving full anticoagulation?
• 0042 — How do patients with dysfibrinogenemia present?
• 0041 — What are good resources for rare clotting factor deficiency?
• 0040 — What is the evidence surrounding prophylaxis in VWD (specifically type 3)?
• 0039 — If I want to achieve a higher trough FVIII level, which is better — increasing the dose or the frequency?
• 0038 — What evidence is there to support the FVIII and FIX targets in the guidelines around the time of surgery?
• 0036 — What data supports the use of sirolimus in refractory ITP?
• 0034 — Should we perform bone marrow biopsies in patients with ITP?
• 0033 — What is the influence of race and ethnicity on the diagnosis of VWD?
• 0032 — How does congenital dysfibrinogenemia present in women?
• 0031 — What are the mechanisms of acquired von Willebrand syndrome?
• 0030 — What is considered a safe threshold for neuraxial anesthesia in patients with bleeding disorders?
• 0028 — Should patients with antiphospholipid antibody syndrome without thrombotic or obstetric complications receive aspirin for primary prophylaxis?
• 0027 — Can emicizumab be used to treat patients with severe type 3 VWD?
• 0026 — Can persons with hemophilia receive antithrombotic therapy?
• 0021 — How do you diagnose bleeding disorders of unknown cause (BDUC)?
• 0018 — Describe the natural history, definition, diagnosis, investigations, and management of patients with confirmed and suspected VWD.
• 0016 — What treatment options are available for patients with FVII deficiency?
• 0015 — What is your approach to the use of porcine FVIII in acquired hemophilia A?
• 0014 — How do you choose between steroids, cyclophosphamide, and rituximab for inhibitor elimination in acquired hemophilia A?
• 0013 — What is the correlation between factor VIII levels and bleeding in carriers of hemophilia A?
• 0012 — What is the difference between hemophilia carriers and hemophilia?
• 0011 — Can you use TPO-RAs in patients with ITP and positive APLAs?
• 0010 — Can patients with persistent or chronic ITP eventually stop treatment with TPO-RAs?
• 0008 — Is IVIG use in ITP associated with increased risk of thrombosis?
• 0007 — What tests for qualitative platelet function defects do we have available, and how can they influence management in clinic?
• 0006 — In frail elderly patients who are stable on warfarin for stroke prevention from atrial fibrillation, can you switch them to a DOAC? And does that lead to harm?
• 0005 — How can someone who has a low factor VIII level of around 40% be considered to possibly have type 2N VWD?
• 0004 — What is the F8 gene duplication (FVIII Padua)?
• 0003 — Can we use Altuviiio (efanesoctocog alfa) for patients who have a history of inhibitors and underwent ITI?
• 0002 — Explain why there is discordance in FVIII activity after AAV gene therapy between one-stage (OS) and chromogenic substrate (CS) assays.
• 0001 — Why is there a discrepancy between clot-based one-stage assays and chromogenic assays in patients who have undergone gene therapy for hemophilia B?